News Headlines Article

Amgen to pay $762 million in misbranding case
Modern Healthcare

Amgen, the world’s largest biotechnology firm, pleaded guilty in federal court in New York to criminal charges that it illegally misbranded its anemia drug Aranesp and agreed to pay $762 million in criminal fines and a civil settlement. The Thousand Oaks, Calif.-based company entered its guilty plea earlier today and has agreed to pay $136 million in criminal fines and $14 million in forfeiture, according to the U.S. Attorney’s Office for the Eastern District of New York. The total settlement, which was not disclosed by the U.S. attorney’s office, will include a $612 million civil settlement, according to a law firm representing a whistle-blower who was involved in the investigation.